New scanner used for brain tumour patients trialled in world-first
A 'pioneering' new scanner derived from MRI technology could be used to track brain cancer spread and lead to improved treatment for patients, researchers have said.
Scientists at the University of Aberdeen and NHS Grampian have been awarded £350,000 of Scottish Government funding to generate never-before-seen images of glioblastoma brain tumours.
The technology is hoped to potentially improve treatment and quality of life for patients, by investigating a new way to scan glioblastoma brain tumours – the most common and aggressive type, with more than 3,000 new patients in the UK diagnosed each year.
Half of all patients die within 15 months of diagnosis even after extensive surgery, radiotherapy and chemotherapy.
Field cycling imaging (FCI) is a new and specialist type of low-field MRI scan pioneered in Aberdeen and has already been found to be effective in detecting tumours in breast tissue and brain damage in stroke patients.
It is hoped it can now be used to help brain tumour patients.
MRI scanners were invented at the University of Aberdeen 50 years ago, but the new FCI scanner is the only one of its type used on patients anywhere in the world.
The FCI derives from MRI but can work at low and ultra-low magnetic fields which means it is capable of seeing how organs are affected by diseases in ways that were previously not possible, and can vary the strength of the magnetic field during the patient's scan – acting like multiple scanners and extracting more information about the tissues.
The new technology can detect tumours without having to inject dye into the body, which can be associated with kidney damage and allergic reactions in some patients.
The team of doctors and scientists involved will scan glioblastoma patients undergoing chemotherapy after surgery and chemoradiotherapy.
It is hoped the research will establish that, unlike conventional MRI scans, FCI can tell the difference between tumour growth and progression, and 'pseudo-progression' which looks like tumour but is not cancerous tissue, which could improve care and quality of life.
Professor Anne Kiltie, Friends of ANCHOR chair in clinical oncology at the University of Aberdeen, who is leading the study said: 'We already have evidence that FCI is effective in detecting tumours in breast tissue and brain damage in patients following a stroke.
'Applying this exciting new technology to glioblastoma patients could give us a much more accurate and detailed picture of what is going on in their brain.
'If we can detect true tumour progression early, we can swap the patient to a potentially more beneficial type of chemotherapy.
'Also, being able to verify that a patient has pseudo-progression will prevent effective chemotherapy being stopped too early, because it was thought that the tumour has progressed, thus worsening prognosis.
'Providing certainty will also reduce anxiety for both patients and relatives and improve the quality of life of patients.
'Importantly, having a reliable method to identify progressive disease will allow development and more precise evaluation of emerging potential treatments. This is of particular importance as patients currently have a limited choice of treatments for combating their cancer.
'Ultimately, this study and related future work will improve quality, effectiveness and healthcare cost-effectiveness in the treatment of glioblastoma patients across Scotland and beyond.'
Sarah-Jane Hogg, chief executive at Friends of ANCHOR, added: 'This is a really promising development and another example of the pioneering work coming out of the University of Aberdeen.
'Professor Kiltie's role at the University is fully funded by Friends of ANCHOR through our Dream Big appeal, and our thanks go to our donors and fundraisers for the part they've played in supporting this work.'
A spokesperson for The Brain Tumour Charity said: 'This pioneering technology is a promising step forward for people who have been diagnosed with the most aggressive type of brain tumour.
'It's positive news in contrast to the accounts we often hear about delays to diagnosis, limited treatment options, and the struggle to get vital innovations to the NHS front line.
'We welcome this, and The Brain Tumour Charity will continue working with clinicians and policymakers in Scotland – and the rest of the UK – to help bring advances to patients more quickly.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Herald Scotland
an hour ago
- The Herald Scotland
Why our politicians must declare a mental health emergency
Most people don't know these statistics – perhaps we would rather not know. But we need to face up to this mental health emergency as only then can we start to recover. We're using the lead-up to next year's Scottish Election to go public with our concerns. This week we launched our manifesto, a passionate plea to politicians and voters at this time of both crisis and opportunity. We gathered contributions from a remarkable number of our 1,500 colleagues – this is the authentic voice of our College. We're not a trade union but a professional body of senior medical doctors which promotes and hallmarks high standards to keep patients safe. We speak out for some of the most vulnerable members of society and have the experience and skills to advise on Scotland's mental health emergency. As psychiatrists we treat people who suffer from serious and complex mental conditions. We use both biological treatments which are usually medications and psychological approaches, such as talking therapies. Above all our work takes place within trusting, confidential relationships. This takes time and enough staff. Not everything is about money but shrinking finances and further unfair cuts make our work impossible. Listening to the expertise of our senior doctors will help ensure that every pound spent on mental health care goes to where it can do most good. The percentage of Scots reporting mental health conditions more than doubled and increased six-fold in young people between 2011 and 2022. When the current government came to power, psychiatry was already a 'Cinderella' service with only 9% of the frontline medical budget. This government promised to deliver 10% with a further 1% for Child and Adolescent Services. By 2022/23 the spend was down to 8.53% – a £238.5 million shortfall. We lost 22% of the permanent psychiatric workforce between 2014 and 2024. One in four consultant posts are vacant or filled by locums. Delivering that 10% funding promise could do much in this crisis. A comprehensive plan for people with neurodiverse conditions is essential too – as they are currently not counted on waiting lists. Adults may not even have access to a list. Members and trainees on the frontline of practice tell us their energy and idealism are giving way to burnout and 'moral injury'' – guilt that inadequate resources prevent us from giving patients what they need to recover and live full lives. These patients are often unable to advocate for their own treatment. Their lives are significantly shortened – their chronic suffering wastes potential and damages society in every way. The Scottish Government presents a positive spin but when we properly analyse the data, the picture is much more concerning. We call on all those in power to declare a mental health emergency. Then we can all work together to start saving lives. Dr Jane Morris, chair of the Royal College of Psychiatrists in Scotland Agenda is a column for outside contributors. Contact: agenda@
Sky News
an hour ago
- Sky News
'Pioneering' new scanner used for brain tumour patients trialled in world-first
A "pioneering" new scanner derived from MRI technology could be used to track brain cancer spread and lead to improved treatment for patients, scientists have said. Researchers at the University of Aberdeen and NHS Grampian have been awarded £350,000 funding by the Scottish government to generate never-before-seen images of glioblastoma brain tumours. It is hoped the technology will improve treatment and quality of life for patients by investigating a new way to scan the tumours. Glioblastoma is the most common and aggressive type of brain tumour with more than 3,000 new patients in the UK diagnosed each year. The University of Aberdeen said half of all patients die within 15 months of diagnosis even after extensive surgery, radiotherapy and chemotherapy. Field cycling imaging (FCI) is a new and specialist type of low-field MRI scan pioneered in Aberdeen and has already been found to be effective in detecting tumours in breast tissue and brain damage in stroke patients. It is hoped it can now be used to help brain tumour patients. Full body MRI scanners were invented at the Scottish university 50 years ago, but the FCI scanner is the only one of its type used on patients anywhere in the world. The FCI derives from MRI but can work at low and ultra-low magnetic fields, which means it is capable of seeing how organs are affected by diseases in ways that were previously not possible. It can also vary the strength of the magnetic field during the patient's scan - acting like multiple scanners and extracting more information about the tissues. The tech can detect tumours without having to inject dye into the body, which can be associated with kidney damage and allergic reactions in some patients. Those involved in the project will scan glioblastoma patients undergoing chemotherapy after surgery and chemoradiotherapy. It is hoped the research will establish that, unlike conventional MRI scans, FCI can tell the difference between tumour growth and progression, and "pseudo-progression" which looks like tumour but is not cancerous tissue, which could improve care and quality of life. The new tech was described as "another example of the pioneering work coming out of the University of Aberdeen", by the charity Friends of ANCHOR. Professor Anne Kiltie, who is leading the study, said: "If we can detect true tumour progression early, we can swap the patient to a potentially more beneficial type of chemotherapy. "Also, being able to verify that a patient has pseudo-progression will prevent effective chemotherapy being stopped too early, because it was thought that the tumour has progressed, thus worsening prognosis. "Providing certainty will also reduce anxiety for both patients and relatives and improve the quality of life of patients. "Importantly, having a reliable method to identify progressive disease will allow development and more precise evaluation of emerging potential treatments. This is of particular importance as patients currently have a limited choice of treatments for combating their cancer. Scotland and beyond."
BBC News
2 hours ago
- BBC News
Aberdeen scanner study could improve brain tumour treatments
Scientists at the University of Aberdeen and NHS Grampian have secured funding to generate never-before-seen brain tumour images with the aim of improving of all glioblastoma patients die within 15 months of diagnosis even after surgery, radio and scans used to monitor a tumour's behaviour can be imprecise but it is hoped the Field Cycling Imaging (FCI) scanner - developed in Aberdeen - will give clinicians better £350,000 in support - from the Scottish government - will fund a trial which will be carried out on a group of 18 patients. MRI scanners were invented at the University of Aberdeen 50 years ago, but the new FCI scanner is the only one of its type used on patients anywhere in the can work at low and ultra-low magnetic fields which means it is capable of seeing how organs are affected by diseases in ways that were not previously can vary the strength of the magnetic field during the patient's scan - acting like multiple scanners and extracting more information about the new technology can detect tumours without having to inject dye into the body, which can be associated with kidney damage and allergic reactions in some team of doctors and scientists involved will scan glioblastoma patients undergoing chemotherapy after surgery and chemoradiotherapy. It is hoped the research will establish that, unlike conventional MRI scans, FCI can tell the difference between tumour growth and progression, and "pseudo-progression" which looks like a tumour but is not cancerous Anne Kiltie, chair in clinical oncology at the University of Aberdeen, who is leading the study, said: "We already have evidence that FCI is effective in detecting tumours in breast tissue and brain damage in stroke patients."Applying this exciting new technology to glioblastoma patients could give us a much more accurate and detailed picture of what is going on in their brain."If we can detect true tumour progression early, we can swap the patient to a potentially more beneficial type of chemotherapy."Providing certainty will also reduce anxiety for both patients and relatives and improve the quality of life of patients."Prof Kiltie's role at the university is fully funded by the charity Friends of ANCHOR through its Dream Big executive Sarah-Jane Hogg welcomed the "really promising" development and thanked donors and fundraisers for their support.
